Search Results

March 29, 2022

U.S. FDA Approves CABENUVA (cabotegravir and rilpivirine) for Adolescents, Expanding the Indication of the First and Only Complete Long-Acting Injectable HIV Regimen

CABENUVA offers virologically suppressed adolescents 12 years of age or older living with HIV-1 an injectable treatment option with as few as six dosing days per year

March 29, 2022

Johnson & Johnson Statement on War in Ukraine

March 25, 2022

New Data Show Majority of Adults with Moderate to Severe Plaque Psoriasis Treated with First-in-Class TREMFYA® (guselkumab) Experienced Durable Skin Clearance Through Five Years Regardless of Metabolic Syndrome Status, Baseline Disease Severity, or Treatment History

Post hoc analysis shows TREMFYA responders reported clinically significant improvements across measures of social and sexual function and fatigue Pooled analysis of seven Phase 2/3 studies of TREMFYA in moderate to severe plaque psoriasis shows a consistent safety profile and no new safety signals

Innovative Medicine

March 24, 2022

U.S. FDA Approves Streamlined Process for Initiating HIV Therapy with CABENUVA (cabotegravir and rilpivirine), the First and Only Complete Long-Acting Injectable HIV Treatment

Adults living with HIV now have an option to start injectable regimen without the need for an oral lead-in period first

March 24, 2022

Johnson & Johnson Announces Series of Youth Initiatives Aimed at Helping to Empower a Generation to End Tuberculosis

Initiatives will focus on engaging young people as advocates in the fight against TB in high-burden countries and regions, including China, India, Southeast Asia and South Africa Youth can help drive health-seeking behavior in themselves and those around them, which is critical to finding the “missing millions” of people living with undiagnosed TB These efforts are part of the Company’s 10-year initiative aimed at helping to bring an end to the global TB epidemic, which claimed 1.5 million lives in 2020

Health & wellness

March 24, 2022

“We want a world without tuberculosis in our lifetimes”

Healthcare providers who contracted TB on the job. A microbiologist researching new treatments. An activist ensuring attention is paid to one of the world’s greatest health threats. These young leaders share one goal: to help end TB.

Global Health Equity

March 23, 2022

Nurturing health worker resilience in Latin America

The Johnson & Johnson Center for Health Worker Innovation is working with partners across Latin America to support the well-being and resilience of frontline health workers and to build the capacity of health systems to provide that support.

Innovative Medicine

March 23, 2022

Janssen Initiates First-of-its-Kind Clinical Study to Bridge Critical Gaps in Care for People of Color with Moderate to Severe Plaque Psoriasis

The only large-scale prospective study in dermatology designed to generate key disease insights among Black, Hispanic, Asian, Indigenous and other people of color Study reinforces Janssen’s commitments to inclusive clinical research and addressing health inequities

Impact Ventures

March 21, 2022

How borderless mentorship helped South Lake Medical Centre bloom

The partnership with SLMC shines light on another aspect of J&J Impact Ventures, an investment fund within the J&J Foundation, offerings: J&J employees as mentors, who engage directly with staff on strategy and other aspects of the work to accelerate progress.

Global Health Equity

March 18, 2022

President Biden signs into law bipartisan landmark bill supporting mental health of U.S. health workers

Johnson & Johnson partnered with the Lorna Breen Heroes’ Foundation to advance the Dr. Lorna Breen Health Care Provider Protection Act (H.R. 1667), the first ever federal legislation directed at protecting the mental health of our nation’s health workforce by ending the culture of fear among healthcare professionals who seek mental health support and treatment.

Search Results

No Results

Search Results